REmAb® De Novo Antibody Sequencing by Mass Spectrometry.
Our antibody sequencing service determines the amino acid sequence of monoclonal antibodies with our proprietary high-throughput, full coverage, de novo antibody sequencing technology.
How Antibody Sequencing Works.
How It Works.
The REmAb® de novo antibody sequencing workflow delivers the complete antibody sequence, including complementarity determining regions (CDR), with unparalleled accuracy and reliability. Starting with just 50μg of purified antibody, the sample undergoes multi-enzyme digestions and the fragments are measured with LC-MS/MS to derive the de novo peptide sequences. These fragments are then analyzed by Rapid Novor’s suite of bioinformatics algorithms to assemble the full-length heavy and light chain antibody sequences. Monoclonal antibody sequencing works on any species and isotype.
Our sequencing platform delivers high quality coverage across the full antibody sequence, variable region and constant region, with hundreds of overlapped peptides. This is a de novo sequencing method – it does not require database or sequence data for reference or homology.
| REmAb |
|---|
| Highest throughput: 50 to 100 mAbs per week |
| Highest accuracy: 100% |
| Lowest sample requirement: 50 μg |
| Most enzymes: 5-10 digests |
| Proprietary, next generation algorithms |
| Ile/Leu calls with WILD and WILDtag technology |
| Ability to handle the unexpected |
| Highest coverage: 100X |
| One sequence that works, every time |
WILD® Isoleucine-Leucine Determination.
Isobaric combinations with confidence: our patented WILD® method was the first commercial service to use additional peptide fragmentation via electron transfer high collision energy dissociation (EThcD) to create and analyze w-ions. This enables true Isoleucine-Leucine determination based on experimental evidence alone. Our unique and patented WILDtag chemistry increases coverage and confidence in isobaric assignments.
De Novo Sequencing of Any Isotype From Any Species.
We’ve worked with all isotypes and popular constructs, including bispecific, chimeric antibodies, nanobodies and fAbs. Secure 100% coverage of variable domains and obtain antibody sequences that recognize the right antigen with our de novo sequencing service.
World Leading Experts In De Novo Antibody Sequencing.
Our team comprises of experienced leaders in mass spectrometry proteomics, protein chemistry and bioinformatics. Even if your sample doesn’t meet our minimum requirements, come talk to us. REmAb® de novo antibody sequencing is an important tool for scientists in sequence analysis, particularly for the identification and characterization of novel antibodies.
Success Stories.
“You are certainly the best CRO we’ve ever worked with!❤️”
“We’ve focused on coupling cytokines with highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to grant them into our platform and test in vitro and in vivo”
“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target – and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands”
100% of survey respondents were happy with the experience
Survey respondents were 9.7/10 likely to refer their peers.
85% of survey respondents were already successful downstream. Remainder were in progress. No reported failure.
The REmAb® Advantage.
| REmAb® | Others | |
|---|---|---|
| Throughput | 50 to 100 mAbs per week | Single runs |
| Accuracy | 100% | Often low / ambiguous |
| Sample volume requirement | 50 μg of antibody protein (as low as 7μg) | >150 μg |
| Multi-enzyme digest | At least 5 – 10 enzymes | 1 or 2 |
| Bioinformatics software | Proprietary, next generation algorithms | Previous generation commercial software |
| Accurate Ile/Leu Determination | Yes, WILD® and WILDtag technology | Rarely |
| Ability to handle the unexpected | Yes: additional chains, impurities, oligos, etc. | Rarely |
| Depth of coverage | 100X | Low or patchy |
| Downstream impact | One sequence that works, every time | Costly ambiguities to express and test |
Getting Started.
Requirements.
- >50 μg of monoclonal antibody
- >80% purity
- Any isotype from any species
Is your antibody sample smaller or less pure? We’ve sequenced many mAbs when the sample amount was much less than our requirements.
Talk to a scientist about your sample.
Deliverables.
- Complete antibody sequence in FASTA
- Interactive peptide coverage viewer and report
- Notable observations
Turn-Around Time.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics
Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.
The Science of Antibody Protein Sequencing.
REmAb® De Novo Antibody Sequencing Applications.
Facilitate in silico design, rational engineering, humanization, chimerization, affinity maturation, conjugation design and construction of fragments and multi-specifics.
Identify novel targets for therapy or diagnosis. de novo sequence and generate recombinant antibodies for downstream binding affinity or specificity enhancement.
Other Protein Characterization Services.
Antibody Sequencing & Discovery Services.
REpAb®
Polyclonal protein sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Explore REpAb®
SPR Analysis
Label-free evaluation of protein-antigen binding relies on a Surface Plasmon Resonance technology. Combined with our expertise in protein interactions, this results in high sensitivity and the lowest noise even in complex analytes.
Explore SPR Analysis
HDX-MS
Mass spectrometry-based epitope mapping identifies the binding site of a protein or compound to its corresponding antigen. Our state-of-the-art instrumentation enables this analysis with the highest confidence and resolution.
